Versa Vascular — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Versa Vascular is an emerging player in the structural heart space, targeting the large and underserved market of tricuspid regurgitation (TR). The company is developing a catheter-based implant and delivery system that sits in the right atrium, aiming for a procedure that is stable, precise, and repositionable. Backed by a $27.3M Series C round and led by a team with deep structural heart expertise, Versa operates from the Occam Labs incubator ecosystem, positioning itself to advance its technology through development and toward clinical trials.

CardiovascularStructural Heart Disease

Technology Platform

Transcatheter tricuspid valve repair system featuring an intra-atrial implant designed to work with native leaflets and a repositionable delivery system for precise placement.

Opportunities

The tricuspid valve repair market is a large, underserved opportunity with an estimated 1.6 million patients in the US alone, where surgical options are high-risk.

The shift towards minimally invasive transcatheter therapies creates a new, rapidly growing market segment.

A differentiated, easy-to-use technology that demonstrates strong clinical outcomes could capture significant market share or attract acquisition interest from larger medtech companies.

Risk Factors

The company faces intense competition from well-funded, established players like Abbott and Edwards Lifesciences who are ahead in development and commercialization.

As a pre-clinical company, there is high technical and clinical risk that the device may not perform as intended in human trials.

Navigating the complex regulatory pathway for a Class III implantable device is a lengthy and costly process with no guarantee of approval.

Competitive Landscape

The transcatheter tricuspid intervention space is highly competitive. Abbott's TriClip is already FDA-approved and commercially available, setting a high bar. Edwards Lifesciences has multiple technologies in development, including the EVOQUE system. Other competitors include startups like Cardiovalve, Medtronic, and Boston Scientific. Versa's key differentiator is its atrial-only positioning, which it must prove offers advantages in safety, efficacy, or ease of use.

More companies in Drug Delivery & Formulation →More companies in United States →